Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

ALS Untangled finds no proven benefit for melatonin in ALS

Original source

MelatoninALSUntangled · 2 June 2021 (opens in a new tab)

Melatonin has plausible biological mechanisms and mixed preclinical evidence, according to an ALS Untangled review. Two case reports linked melatonin, as part of treatment combinations, with recovery of lost motor function, while a very small retrospective study suggested slower progression and longer survival. The evidence does not establish that melatonin slows ALS progression, or the best dose or delivery method.

Why this matters

Melatonin may be worth studying in a pilot trial, but ALS Untangled does not recommend it as an ALS treatment based on current evidence. The reported motor recovery cannot be attributed to melatonin alone because it was used alongside other treatments.

Limitations and context

This is an expert review, not a new clinical trial. The case reports involved treatment cocktails, and the retrospective study was very small and flawed. The review also reports mixed preclinical findings, and no proven benefit, optimal dose, or administration route has been established.

Summarised by Compass 10 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?